PTGX
Protagonist Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$145.11
−2.48%Aug 28, 2026, 21:39 UTC
The U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.
Aug 5, 2026, 22:26 UTC
Protagonist Therapeutics reported Q2 2026 earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share, compared to a loss of $0.55 per share a year ago.
Source: